Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2006

01-05-2006 | Image of the month

Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour

Authors: Mark Beresford, Bal Sanghera, Wai-Lup Wong, Andreas Makris

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2006

Login to get access

Excerpt

The assessment of the proliferative activity of breast cancers has been shown to be of prognostic significance [1]. Until recently this has required patients to undergo biopsies for application of histological and immunochemical techniques for measurement of proliferation (such as Ki67 staining, flow cytometry or thymidine labelling index). It is thought that changes in proliferative activity over a course of treatment might be an early indication of response. A decrease in Ki67 score after one cycle of neoadjuvant chemotherapy has been shown to predict a good clinical response [2]. Breast cancers are heterogeneous in proliferative activity and this may influence results from techniques which require tissue samples [3]. …
Literature
1.
Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984;33:441–445PubMedCrossRef
2.
Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058–3063PubMed
3.
Going JJ, Stanton PD, Cooke TG. Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labeled in vivo with bromodeoxyuridine. Am J Clin Pathol 1993;100:218–222PubMed
Metadata
Title
Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour
Authors
Mark Beresford
Bal Sanghera
Wai-Lup Wong
Andreas Makris
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-0037-7

Other articles of this Issue 5/2006

European Journal of Nuclear Medicine and Molecular Imaging 5/2006 Go to the issue

Editorial

18F-DOPA PET/CT and neuroendocrine tumours

Original Article

99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody

Original article

Fully automatic diagnostic system for early- and late-onset mild Alzheimer’s disease using FDG PET and 3D-SSP

Original article

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent

Original Article

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours

Short communication

Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis